Sage Journals: Discover world-class research

Retricted access

Review article

First published 2019-1

FLT3 inhibitors in acute myeloid leukemia: Current and future

Christan M Thomas, Peter Campbell

Journal of Oncology Pharmacy Practice

Free access

Research article

First published 2010-10

Antileukemic Effects of Novel First- and Second-Generation FLT3 Inhibitors

Ellen Weisberg, Johannes Roesel, Pascal Furet [...]

Genes & Cancer

Retricted access

Research article

First published 2022-9

Real world use of FLT3 inhibitors for treatment of FLT3+ acute myeloid leukemia (AML): A single center,propensity-score matched,retrospective cohort study

Brian G Bazzell, Bernard L Marini, Lydia L Benitez [...]

Journal of Oncology Pharmacy Practice

Open access

Research article

First published 2024

A disproportionality analysis for assessing the safety of FLT3 inhibitors using the FDA Adverse Event Reporting System (FAERS)

Jie Zhou, Jinping Zhang, Qiaoyun Wang [...]

Therapeutic Advances in Drug Safety

Open access

Review article

First published 2019

Emerging treatment paradigms with FLT3 inhibitors in acute myeloid leukemia

Nicholas J. Short, Hagop Kantarjian, Farhad Ravandi [...]

Therapeutic Advances in Hematology

Free access

Review article

First published 2014-6

The evolving role of FLT3 inhibitors in acute myeloid leukemia: quizartinib and beyond

Seth A. Wander, Mark J. Levis, Amir T. Fathi

Therapeutic Advances in Hematology

Open access

Review article

First published 2019

Allogeneic transplant for FLT3 - ITD mutated AML: a focus on FLT3 inhibitors before,during,and after transplant

Abdul Hamid Bazarbachi, Rama Al Hamed, Florent Malard [...]

Therapeutic Advances in Hematology

Free access

Research article

First published 2012-7

The STAT5 Inhibitor Pimozide Displays Efficacy in Models of Acute Myelogenous Leukemia Driven by FLT3 Mutations

Erik A. Nelson, Sarah R. Walker, Michael Xiang [...]

Genes & Cancer

Free access

Research article

First published 2010-2

Wnt/β-catenin Pathway Modulates the Sensitivity of the Mutant FLT3 Receptor Kinase Inhibitors in a GSK-3β Dependent Manner

Jingrui Jiang, James D. Griffin

Genes & Cancer

Open access

Review article

First published 2020

Gilteritinib in the treatment of relapsed and refractory acute myeloid leukemia with a FLT3 mutation

Serena Chew, Melissa C. Mackey, Elias Jabbour

Therapeutic Advances in Hematology

Search results